Rectum Cancer Clinical Trial
Official title:
Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy With Selective Radiotherapy Use in Patients With Intermediate-Risk Cancer of the Rectum Defined by Magnetic Resonance Imaging
Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy (CAPECITABINE-OXALIPLATIN + BEVACIZUMAB) with Selective Radiotherapy and Chemotherapy with CAPECITABINE Use in Patients with Intermediate-Risk Cancer of the Rectum Defined by Magnetic Resonance Imaging.
XELOX / Bevacizumab will be administrated for 3 cycles over a 9 week period. XELOX without Bevacizumab will be administrated for an additional cycle over a 4 week period. Patients will undergo re-staging within 3 weeks of their 4th cycle of XELOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 4 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous Capecitabine. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Completed |
NCT00409994 -
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04371198 -
Patient-Derived Organoids for Rectal Cancer
|
N/A | |
| Recruiting |
NCT04916990 -
Improving Care for Rural Patients With Solid Tumors
|
N/A | |
| Active, not recruiting |
NCT05305820 -
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
|
N/A | |
| Recruiting |
NCT03699761 -
The Role of Pelvic Peritonization in Laparoscopic or Robotic Low Anterior Resection
|
N/A | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Completed |
NCT03843957 -
Effectiveness and Implementation of mPATH-CRC
|
N/A | |
| Completed |
NCT02423226 -
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
|
Phase 2 | |
| Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
| Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
| Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
| Not yet recruiting |
NCT06066931 -
Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE
|
N/A | |
| Recruiting |
NCT02738359 -
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
|
||
| Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT02458664 -
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
|
N/A | |
| Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
| Recruiting |
NCT05715255 -
Adaptive Symptom Self-Management Immunotherapy Study
|
N/A | |
| Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
| Recruiting |
NCT04405206 -
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
|